GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (NAS:SLGC) » Definitions » Cost of Goods Sold

SomaLogic (SomaLogic) Cost of Goods Sold : $48.09 Mil (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SomaLogic Cost of Goods Sold?

SomaLogic's cost of goods sold for the three months ended in Sep. 2023 was $11.64 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Sep. 2023 was $48.09 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. SomaLogic's Gross Margin % for the three months ended in Sep. 2023 was 47.23%.

Cost of Goods Sold is also directly linked to Inventory Turnover. SomaLogic's Inventory Turnover for the three months ended in Sep. 2023 was 0.80.


SomaLogic Cost of Goods Sold Historical Data

The historical data trend for SomaLogic's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomaLogic Cost of Goods Sold Chart

SomaLogic Annual Data
Trend Dec20 Dec21 Dec22
Cost of Goods Sold
22.61 33.46 43.36

SomaLogic Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.67 12.97 12.32 11.18 11.64

SomaLogic Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $48.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SomaLogic  (NAS:SLGC) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

SomaLogic's Gross Margin % for the three months ended in Sep. 2023 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(22.048 - 11.635) / 22.048
=47.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

SomaLogic's Inventory Turnover for the three months ended in Sep. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


SomaLogic Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of SomaLogic's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


SomaLogic (SomaLogic) Business Description

Traded in Other Exchanges
N/A
Address
2945 Wilderness Place, Boulder, CO, USA, 80301
SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.
Executives
Alison Marie Roelke officer: Chief People Officer 900 INNOVATORS WAY, SIMI VALLEY CA 93065
Adam Taich officer: Interim CEO C/O SOMALOGIC, INC., 2945 WILDERNESS PLACE, BOULDER CO 80301
Ruben Gutierrez officer: General Counsel 6435 AVENIDA WILFREDO, LA JOLLA CA 92037
Kathy L Hibbs director C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
Jason Ryan director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas D. Carey director 8 PAIGE STREET, HINGHAM MA 02043
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Tycho Peterson director C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Shaun M. Blakeman officer: Chief Financial Officer C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Anne H. Margulies director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Richard A Post director 998 LACOSTA LANE, LANE TREE CO 80124
Charles M. Lillis director 13 CASTLE PINES DRIVE N, CASTLE ROCK CO 80108
Stephen Quake director C/O FLUIDIGM CORPORATION, 7000 SHORELINE COURT, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Robert Barchi director

SomaLogic (SomaLogic) Headlines

From GuruFocus